Activities of erythropoietin on tumors: An immunological perspective

Ghezzi, Pietro; Mengozzi, Manuela

doi:10.1002/eji.200737401

Cited by 8 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, such functions include neuroprotection (Brines et al 2004, Cilloni et al 2004, anti-neoplastic activity (Mittelman et al 2001, Katz et al 2005, and improvement in congestive heart failure (Silverberg et al 2002, Fiordaliso et al 2005, Camici et al 2007. We (Prutchi-Sagiv et al 2006a,b, 2008, Ghezzi & Mengozzi 2007, Katz et al 2007, Lifshitz et al 2009), as well as others (Ghezzi & Mengozzi 2007), have found EPO-associated improvement in immunological functions.…”

Section: Introductionmentioning

confidence: 57%

Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

Katz¹,

Stuible²,

Golishevski³

et al. 2010

Journal of Endocrinology

View full text Add to dashboard Cite

Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor cells into erythrocytes. The last decade has revealed non-renal sites of EPO production and extrahematopoietic expression of the EPO receptor, thus suggesting that EPO has pleiotropic functions. Here, we addressed the interplay between EPO/glucose metabolism/ body weight by employing a panel of relevant experimental murine models. The models focused on situations of increased EPO levels, including EPO-injected C57BL/6 and BALB/c mice, as well as transgenic mice (tg6) constitutively overexpressing human EPO, thus exposed to constantly high EPO serum levels. As experimental models for diabetes and obesity, we employed protein Tyr phosphatase 1B (PTP1B) knockout mice associated with resistance to diabetes (PTP1B K/K ), and ob/ob mice susceptible to diabetes and obesity. The data presented herein demonstrate EPOmediated decrease in blood glucose levels in all mice models tested. Moreover, in the ob/ob mice, we observed EPOmediated attenuation of body weight gain and reduction of hemoglobin A1c. Taken together, our data bear significant clinical implications of EPO treatment in the management of a wide range of metabolic diseases, thus adding an important novel therapeutic potential to this pleiotropic hormone.

show abstract

Section: Introductionmentioning

confidence: 57%

Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

Katz¹,

Stuible²,

Golishevski³

et al. 2010

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Viceversa, recombinant human EPO (rhEPO) is able to augment the antineoplastic efficiency of T cells and humoral immunity ( Katz et al, 2007 ; Nairz et al, 2012 ). Furthermore, treatment of patients with cancer using rhEPO increased T lymphocyte function regarding blastic response ( Ghezzi and Mengozzi, 2007 ).…”

Section: Clinical Relevance Of Cramentioning

confidence: 99%

Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach

Gramignano²,

et al. 2018

View full text Add to dashboard Cite

Cancer-related anemia (CRA) is a common sign occurring in more than 30% of cancer patients at diagnosis before the initiation of antineoplastic therapy. CRA has a relevant influence on survival, disease progression, treatment efficacy, and the patients’ quality of life. It is more often detected in patients with advanced stage disease, where it represents a specific symptom of the neoplastic disease, as a consequence of chronic inflammation. In fact, CRA is characterized by biological and hematologic features that resemble those described in anemia associated to chronic inflammatory disease. Proinflammatory cytokine, mainly IL-6, which are released by both tumor and immune cells, play a pivotal action in CRA etiopathogenesis: they promote alterations in erythroid progenitor proliferation, erythropoietin (EPO) production, survival of circulating erythrocytes, iron balance, redox status, and energy metabolism, all of which can lead to anemia. The discovery of hepcidin allowed a greater knowledge of the relationships between immune cells, iron metabolism, and anemia in chronic inflammatory diseases. Additionally, chronic inflammation influences a compromised nutritional status, which in turn might induce or contribute to CRA. In the present review we examine the multifactorial pathogenesis of CRA discussing the main and novel mechanisms by which immune, nutritional, and metabolic components affect its onset and severity. Moreover, we analyze the status of the art and the perspective for the treatment of CRA. Notably, despite the high incidence and clinical relevance of CRA, controlled clinical studies testing the most appropriate treatment for CRA are scarce, and its management in clinical practice remains challenging. The present review may be useful to indicate the development of an effective approach based on a detailed assessment of all factors potentially involved in the pathogenesis of CRA. This mechanism-based approach is essential for clinicians to plan a safe, targeted, and successful therapy, thereby promoting a relevant amelioration of patients’ quality of life.

show abstract

“…Asci et al, 2010). There is a growing interest towards the non-erythropoietic, tissue-protective and restorative actions of erythropoietin (EPO) (Ghezzi and Mengozzi, 2007). The accumulated data reveal that EPO exerts pleiotropic activities and suggests a potential novel use of rHuEpo as an immunomodulator (Godai et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

RESEARCH PAPER Neopterin in patients with chronic kidney disease and patients with coronary artery disease

Formanowicz¹

2012

bta

View full text Add to dashboard Cite

Neopterin, a marker of stimulated cellular immune response, levels increase during many disorders. A number of different features of neopterin prompted us to study its serum concentration in patients with all stages of chronic kidney disease (CKD) and patients with coronary artery disease (CARD). To the best of our knowledge this is the first study that evaluates and compares the serum neopterin concentration in those diseases taken together as one study. One hundred and twenty five subjects, divided into five groups, were included in the study. The first three groups consisted of patients with different stages of CKD. CARD patients without CKD and healthy volunteers as controls were also studied. Serum neopterin concentration was measured by an enzyme-linked immunosorbent assay (ELISA, BRAHMS, Hennigsdorf/Berlin, Germany) according to the manufacturers' instructions. We have found that patients with the most advanced stage of CKD had fifteen times higher serum neopterin than patients from other studied groups. Interestingly, in the CKD1-2, CKD3-4 and CARD patients without CKD, serum neopterin concentrations were similar to those obtained from healthy volunteers. Serum urea and serum ferritin appeared to be significant independent predictors of serum neopterin concentration after adjustment for urea, CA-IMT, peripheral systolic blood pressure, ferritin, hsCRP, HD vintage, BMI and eGFR, explaining 95.89% of serum neopterin variations. In conclusion, it seems that despite the existence of many factors that may influence serum neopterin, those derived from impaired renal function and immunological disturbances coming from hemodialysis treatment are crucial. In this study, we observed that the more impaired the renal function, higher is the increase in serum neopterin concentration.

show abstract

Activities of erythropoietin on tumors: An immunological perspective

Cited by 8 publications

References 19 publications

Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach

RESEARCH PAPER Neopterin in patients with chronic kidney disease and patients with coronary artery disease

Contact Info

Product

Resources

About